N/A N=390 Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts
Intumescent Cataract
Primary: Percentage of Capsular Tears (Anterior or Posterior) During Surgery — 5.3; 5.3 percentage of capsular tears
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
N/A N=229 Toric Intraocular Lens Following Cataract Surgery
Cataract · Astigmatism
Primary: Percent Reduction in Absolute Cylinder — 84.975; 46.498 percentage of intended cylinder reduct
Phase 4 N=20 Vault Evaluation After ICL Implantation
Nearsightedness
Primary: Mean Difference Between Predicted and Actual Central Vault at 1-month After ICL Implantation — 0.170 Milimeters
Phase 4 N=44 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
N/A N=262 EYEFILL® C. -US Viscoelastic Clinical Investigation
Cataract
Primary: Mean Percent Cell Change (Preservation of Endothelium) — -10.05; -10.13 percent cell change
N/A N=100 Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF
Capsule Opacification · Pseudophakia · Cataract
Primary: Posterior Capsule Opacification (PCO) — 3.0; 1.9 units on a scale (0-10)
N/A N=114 Infant Aphakia Treatment Study (IATS)
Congenital Cataract
Primary: Visual Acuity — 0.80; 0.97 logMAR units — p=0.19
Phase 2 N=26 Pupil Dilation for Treatment of IFIS
Intraoperative Floppy Iris Syndrome
Primary: Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye — 6.76; 7.17 millimeters
Phase 3 N=1,020 Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)
Cataract
Primary: Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up — 227; 255 participants — p=0.03
N/A N=20 Optimizing the Ocular Surface Prior to Cataract Surgery
Corneal Dystrophy, Epithelial Basement Membrane
Primary: Change in Intraocular Lens Calculation — 1.56; 0.94 D
Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
N/A N=3,785 Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS IOL L313
Posterior Capsule Opacification
Primary: Percentage of Eyes With Posterior Capsule Opacification Following Implantation of IOL 313 up to 8 Years — 7.9; 4.7; 17.1; 8.2 percentage of eyes
Phase 3 N=122 One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction
Aphakia · Cataract
Primary: Visual Acuity — 108 Participants
Phase 4 N=87 Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery
Cataract · Cystoid Macular Edema After Phacoemulsification
Primary: Change in Macular Thickness From Baseline to 6 Weeks Postoperatively After Cataract Surgery — 252.6; 253.1 Microns
Phase 3 N=394 The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Inflammation · Cataracts
Primary: Number of Participants With Anterior Chamber Cell Clearing — 99; 103; 20 Participants
N/A N=35 Vitreous Inflammation in Standard and Heavy Silicone Oil
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
N/A N=37 Endothelial Bleb Response With Toric Lenses
Ametropia
Primary: Endothelial Bleb Areas on Cornea: Session A- Open Eye — 0.1; 2.0; 0.2; 2.1 Percent Difference of Bleb Area
Phase 4 N=79 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Cystoid Macular Edema
Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029
N/A N=11 Triamcinolone vs. Laser for Diabetic Macular Edema
DIABETIC MACULAR EDEMA
Primary: Main Outcome Measures Will be Quantitative Changes in OCT Central Thickness, Visual Acuity, and Number of Snellen Acuity Lines Gained/Lost.
Phase 2 N=146 A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Change in Humphrey Visual Fields - Total Sensitivity — 1.4; 16.8; -164.8; -66.7 dB
N/A N=400 Clinical Evaluation of a New Viscoelastic for Cataract Surgery
Cataract
Primary: Percent of Intraocular Pressure Spikes 30 mm Hg or Greater Postoperatively — 10.6; 7.6 percentage of participants
N/A N=32 Clinical Investigation of an AcrySof IQ PanOptix Toric Intraocular Lens
Aphakia · Corneal Astigmatism
Primary: Percentage of Eyes With ≤ 0.25 Diopter (D) Absolute Refractive Cylinder at Visit 3/3A (Day 30-60) — 90.2 percentage of eyes — p=<0.0001
Phase 3 N=181 Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Cataract
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 53; 13; 1; 0 Participants
N/A N=100 Assessment of Low Energy Lens Fragmentation Cataract Extraction in Patients Undergoing Cataract Surgery
Cataract
Primary: Total Lens Removal Time — 76.0; 80.1 seconds
Phase 4 N=28 Intraoperative Floppy Iris Syndrome
Cataract · Floppy Iris Syndrome
Primary: Corneal Endothelial Cell Loss — 9.85; -3.68 Percent change
N/A N=110 Infrared Choroidal Reflectance Camera for the Detection of Childhood Cataract
Childhood Cataract
Primary: Results of Red-reflex and Infrared-reflex Tests Compared to Gold Standard — 17; 54; 32; 7 eyes